References
- Chow JPH, Poon RYC. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 2013;32:4778–88
- Tibes R, Bogenberger JM, Chaudhuri L, et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 2012;119:2863–72
- Zhou BN, Tang S, Johnson RK, et al. New glycolipid inhibitors of Myt1 kinase. Tetrahedron 2005;61:883–7
- Wu HJ, Li CX, Song GP, Li YX. Synthesis of natural α-6-dehydroxy-6-aminoglucoglycerolipids. Chin J Chem 2008;26:1641–6
- Göllner C, Philipp C, Dobner B, et al. First total synthesis of 1,2-dipalmitoyl-3-(N-palmitoyl-6′-amino-6′-deoxy-alpha-d-glucosyl)-sn-glycerol -- a glycoglycerolipid of a marine alga with a high inhibitor activity against human Myt1-kinase. Carbohydr Res 2009;344:1628–31
- Sun Y, Zhang J, Li C, et al. Synthesis of glycoglycerolipid of 1,2-dipalmitoyl-3-(N-palmitoyl-6′-amino-6′-deoxy-α-d-glucosyl)-sn-glycerol and its analogues, inhibitors of human Myt1-kinase. Carbohydr Res 2012;355:6–12
- Rohe A, Göllner C, Wichapong K, et al. Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay. Eur J Med Chem 2013;61:41–8
- Li C, Sun Y, Zhang J, et al. Synthesis of 6′-acylamido-6′-deoxy-alpha-d-galactoglycerolipids. Carbohydr Res 2013;376C:15–23
- Rohe A, Erdmann F, Bäßler C, et al. In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase. Bioorg Med Chem Lett 2012;22:1219–23
- Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76–85
- Rohe A, Henze C, Erdmann F, et al. A fluorescence anisotropy based Myt1 kinase binding assay. Assay Drug Dev Technol 2014;12:136–44
- Chattopadhyay A, London E. Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge. Anal Biochem 1984;139:408–12
- Wichapong K, Rohe A, Platzer C, et al. Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. J Chem Inf Model 2014;54:881–93
- Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM. Detection of allosteric kinase inhibitors by displacement of active site probes. J Biomol Screen 2012;17:813–21
- Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 2011;29:1046–51
- Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615–19
- Kristjánsdóttir K, Rudolph J. A fluorescence polarization assay for native protein substrates of kinases. Anal Biochem 2003;316:41–9
- Jameson DM, Ross JA. Fluorescence polarisation/anisotropy in diagnostics and imaging. Chem Rev 2010:2685–708
- Roehrl MHA, Wang JY, Wagner G. A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein–protein interactions by pluorescence polarization. Biochemistry 2004;43:16056–66
- Wu G. Assay development: fundamentals and practices. Hoboken (NJ): John Wiley & Sons, Inc., 2010:187–99
- Tang S. Structural and synthetic studies of bioactive natural products. Blacksburg (VA): Virginia Polytechnic Institute and State University; 2005:91–110
- Thorsteinsson MV, Richter J, Lee AL, DePhillips P. 5-Dodecanoylaminofluorescein as a probe for the determination of critical micelle concentration of detergents using fluorescence anisotropy. Anal Biochem 2005;340:220–5
- Munoz L, Selig R, Yeung YT, et al. Fluorescence polarization binding assay to develop inhibitors of inactive p38 alpha mitogen-activated protein kinase. Anal Biochem 2010;401:125–33
- Zegzouti H, Zdanovskaia M, Hsiao KGoueli SA. ADP-Glo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol 2009;7:560–72